Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Harrington, Conn; Sawchak, Sharon; Chiang, Carl; Davies, J.; Donovan, Carly; M. Saunders, Ann; C. Irizarry, Michael; Jeter, Barbara; Zvartau‐Hind, Marina; H van Dyck, C; Gold, Maike

doi:10.2174/156720511796391935

Public

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Published in Current Alzheimer Research • Jul 11, 2011

Authors:

Conn Harrington

Sharon Sawchak

Carl Chiang

Abstract

INTRODUCTION: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to a...

Subject

Placebo

Internal medicine

Donepezil

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!